Organ-sparing radiotherapy in penile cancer: therapeutic approaches.

Int Urol NephrolApr 17, 2026 (epub)
Clinical ResearchRadiology (Diagnostic)UrologyOpen access

Avraam Muresan, Mihai Domnutiu Suciu, Vlad Horia Schitcu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy of low-dose rate (LDR), pulsed-dose rate (PDR), and high-dose rate (HDR) brachytherapy in treating penile squamous cell carcinoma (PSCC). Analyzing 18 studies, the review found that five-year cancer-specific survival rates ranged from 85.0% to 100%. The findings support brachytherapy as a viable organ-sparing option for T1-T2 PSCC.

Key findings

  • Five-year cancer-specific survival rates ranged from 85.0% to 100% across nine studies.
  • Local failures were highly salvageable, with success rates between 77% and 100%.
  • Brachytherapy is confirmed as an effective organ-sparing treatment for T1-T2 penile cancer.

Why it matters

Understanding the effectiveness of organ-sparing treatments like brachytherapy is crucial for improving patient outcomes in penile cancer, reducing the need for more invasive surgeries that can lead to significant morbidity.

Source

PubMed · PMID 41991714Free full text on PubMed Central

Published in Int Urol Nephrol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Radiology (Diagnostic)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.